JP2006516112A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516112A5
JP2006516112A5 JP2004532124A JP2004532124A JP2006516112A5 JP 2006516112 A5 JP2006516112 A5 JP 2006516112A5 JP 2004532124 A JP2004532124 A JP 2004532124A JP 2004532124 A JP2004532124 A JP 2004532124A JP 2006516112 A5 JP2006516112 A5 JP 2006516112A5
Authority
JP
Japan
Prior art keywords
endostatin
pharmaceutical composition
individual
composition according
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004532124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516112A (ja
JP4612417B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/009497 external-priority patent/WO2004020469A2/en
Publication of JP2006516112A publication Critical patent/JP2006516112A/ja
Publication of JP2006516112A5 publication Critical patent/JP2006516112A5/ja
Application granted granted Critical
Publication of JP4612417B2 publication Critical patent/JP4612417B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004532124A 2002-08-28 2003-08-27 眼の遺伝子治療 Expired - Fee Related JP4612417B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
PCT/EP2003/009497 WO2004020469A2 (en) 2002-08-28 2003-08-27 Ocular gene therapy

Publications (3)

Publication Number Publication Date
JP2006516112A JP2006516112A (ja) 2006-06-22
JP2006516112A5 true JP2006516112A5 (cg-RX-API-DMAC10.html) 2010-06-24
JP4612417B2 JP4612417B2 (ja) 2011-01-12

Family

ID=31978303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004532124A Expired - Fee Related JP4612417B2 (ja) 2002-08-28 2003-08-27 眼の遺伝子治療

Country Status (11)

Country Link
US (1) US20070104684A1 (cg-RX-API-DMAC10.html)
EP (1) EP1534751B1 (cg-RX-API-DMAC10.html)
JP (1) JP4612417B2 (cg-RX-API-DMAC10.html)
CN (2) CN100526332C (cg-RX-API-DMAC10.html)
AT (1) ATE464321T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003258675B2 (cg-RX-API-DMAC10.html)
CA (1) CA2496820A1 (cg-RX-API-DMAC10.html)
DE (1) DE60332122D1 (cg-RX-API-DMAC10.html)
IL (1) IL166950A (cg-RX-API-DMAC10.html)
NZ (1) NZ538958A (cg-RX-API-DMAC10.html)
WO (1) WO2004020469A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
ATE298371T1 (de) * 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
AU2001295193A1 (en) * 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
AU2001272932A1 (en) * 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
US20020086007A1 (en) * 2000-10-13 2002-07-04 Sim Kim Lee Angiogenesis-inhibiting peptides and proteins and methods of use
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy

Similar Documents

Publication Publication Date Title
JP7503590B2 (ja) 遺伝子構築物
JP4361734B2 (ja) 血管形成の調節に有用なトリプトファニル−tRNAシンテターゼ由来ポリペプチド
US10463708B2 (en) Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
CN102791283A (zh) 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用
CN110831960A (zh) C末端的cdnf和manf片段、包含它们的药物组合物及其用途
JP7558260B2 (ja) 眼科障害の処置または防止における使用のための薬剤
US9469679B2 (en) Neurturin molecules
EP1379278A2 (en) Method of inducing proliferation of retinal stem cells
US8445432B2 (en) Neurturin molecules
US20140369987A1 (en) Dermaseptin b2 used as an inhibitor of the growth of a tumor
AU2010313456A1 (en) Improved neurturin molecules
HK40072504A (en) Agent for use in treatment or prevention of ophthalmic disorders
CN105017406A (zh) 一类新的具有神经保护功能的多肽
HK1252168B (en) Genetic construct
NZ538958A (en) Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues